Bexarotene-metformin salt as well as preparation method, composition and application thereof

By preparing a 1:1 molar ratio salt of besalotine and metformin, and combining it with a pharmaceutical carrier to formulate various dosage forms, the problem of the lack of drugs for the treatment of type 2 diabetes with psoriasis in the existing technology has been solved, and the effect of significantly improving blood sugar and psoriasis symptoms has been achieved.

CN119019251APending Publication Date: 2024-11-26INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310552168.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There is a lack of oral medications in the current technology that can simultaneously improve the symptoms of type 2 diabetes and psoriasis, especially for patients with type 2 diabetes and psoriasis.

Method used

By preparing a 1:1 molar salt of besalotine and metformin, specific preparation methods and characterization techniques, such as X-ray diffraction, infrared spectroscopy and differential scanning calorimetry, are used to ensure that it is a new solid substance. Subsequently, it is combined with a pharmaceutically acceptable carrier to prepare various dosage forms for administration.

Benefits of technology

Besalotine-metformin salt significantly improves solubility and bioactivity in water, effectively lowers blood sugar levels and improves psoriasis symptoms, providing a pharmaceutical solution for the simultaneous treatment of type 2 diabetes and psoriasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019251A_ABST
    Figure CN119019251A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and discloses Bexarotene-metformin salt as well as a preparation method, a composition and application thereof. The invention relates to a salt formed by Bexarotene as shown in a formula I and metformin. The invention relates to a preparation method of Bexarotene-metformin salt. The invention discloses application of Bexarotene-metformin salt as an active pharmaceutical ingredient in preparation of a medicine for preventing and treating type 2 diabetes mellitus with psoriasis. Bexarotene-metformin salt capable of simultaneously improving psoriasis related symptoms and abnormal glucose and lipid metabolism of diabetes mellitus with psoriasis, # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and relates to a salt formed by bexarotene and metformin, a preparation method thereof, and a composition and use thereof. Specifically, the present invention relates to a salt formed by bexarotene and metformin; a preparation method of a bexarotene-metformin salt; and the use of a bexarotene-metformin salt as a pharmaceutical active ingredient in the preparation of a drug for preventing and / or treating type 2 diabetes with psoriasis. Background Art

[0002] Drug salt formation refers to the process in which a drug combines with another chemical substance (salt-forming ligand, saltformer) through proton transfer to form a new chemical entity, which is an important way to develop new drugs. Traditional salt formation refers to the combination of acidic compounds with metal ions, usually potassium, calcium, sodium, magnesium, etc., to form salts, or refers to the combination of basic drugs with inorganic acids or organic acids, usually hydrochloric acid, sulfuric acid, maleic acid, fumaric acid, etc. to form salts, thereby improving physical and chemical properties, such as stability and solubility, to achieve the purpose of improving drugability. Usually these introduced chemicals do not have pharmacological activity.

[0003] The present invention adopts Bexarotene as the active substance, whose chemical name is 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)vinyl]benzoic acid, and whose molecular formula is C 24 H 28 O2, with the structural formula shown in a. Bexarotene is a retinoic acid analogue, and its physical and chemical properties show that it is a white powder and is insoluble in water. The salt-forming ligand (saltformer) used in the invention is metformin, with the molecular formula of C4H 11 N5, whose structural formula is shown in b, is a biguanide derivative, which is often used in the clinical practice in the form of solid preparations of metformin hydrochloride (mainly tablets or capsules), which is the first-line drug for the treatment of type 2 diabetes. Physical and chemical properties record Metformin hydrochloride is a white powder, which is easily soluble in water.

[0004] Summary of the invention

[0005] One of the purposes of the present invention is to provide an existence state and characterization method of a salt formed by bexarotene and metformin.

[0006] The second object of the present invention is to provide a method for preparing bexarotene-metformin salt.

[0007] The third object of the present invention is to provide a mixed solid substance and a pharmaceutical composition containing a pure bexarotene-metformin salt or a bexarotene-metformin salt mixture in any non-zero ratio.

[0008] The fourth object of the present invention is to provide a pharmaceutical composition using bexarotene-metformin salt as a pharmaceutical active ingredient, wherein the daily dosage of bexarotene is in the range of 300-1500 mg. The pharmaceutical composition includes tablets, capsules, pills, injection preparations, granules, powders, pellets, dropping pills, suppositories, films, patches, aerosols, sprays, sustained-release preparations or controlled-release preparations.

[0009] The fifth object of the present invention is to provide a bexarotene-metformin salt having a better solubility advantage than bexarotene.

[0010] The sixth object of the present invention is to use bexarotene-metformin salt as an active ingredient in the preparation of drugs for preventing and / or treating type 2 diabetes associated with psoriasis.

[0011] The eighth object of the present invention: Metformin is the most widely used drug for the treatment of type 2 diabetes in clinical practice. It can work synergistically with bexarotene to improve the psoriasis symptoms of diabetic patients with psoriasis while lowering blood sugar levels.

[0012] In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0013] 1 Morphological characteristics of bexarotene and metformin salt samples:

[0014] 1.1 The bexarotene-metformin salt of the present invention is characterized in that bexarotene and metformin form a salt in a molar ratio of 1:1.

[0015]

[0016] 1.2 The bexarotene-metformin salt of the present invention is analyzed by powder X-ray diffraction using CuK α Under radiation experimental conditions, diffraction peak position: 2-Theta value (°) or d value Diffraction peak relative intensity: peak height value (Height%) or peak area value (Area%) has the following characteristics (Table 1, Figure 1 ). The X-ray diffraction pattern and data of the physical mixed powder of bexarotene and metformin are shown in Table 2. Figure 2 The X-ray diffraction patterns of the physical mixture powders of bexarotene-metformin salt and metformin hydrochloride and bexarotene were significantly different in terms of the number of diffraction peaks, the positions of the diffraction peaks, the intensity of the diffraction peaks, and the topological patterns of the diffraction peaks, indicating that the physical mixture of bexarotene-metformin salt and metformin hydrochloride and bexarotene was neither the same nor identical.

[0017] Table 1 Powder X-ray diffraction peak values ​​of bexarotene-metformin salt

[0018]

[0019] Table 2 Powder X-ray diffraction peaks of bexarotene and metformin physical mixture

[0020]

[0021] 1.3 The bexarotene-metformin salt of the present invention is characterized in that when analyzed by attenuated total reflection Fourier transform infrared spectroscopy, the results are as follows: 3671, 3497, 3397, 3269, 3018, 2949, 2927, 2862, 1812, 1715, 1669, 1616, 1584, 1538, 1531, 1505, 1462, 1454, 1411, 1378, 131 9. 1280, 1268, 1227, 1186, 1168, 1142, 1111, 1104, 1077, 1064, 1049, 1018, 963, 924, 906, 8 98, 868, 850, 843, 795, 764, 725, 649, 629, 589, 567, 549, 534, 518, 489, 472, 460, 423, 414cm -1 There is a characteristic peak of infrared spectrum at the position, and the allowable deviation of the characteristic peak of infrared spectrum is ±2cm -1 ( Figure 3 ).

[0022] 1.4 The bexarotene-metformin salt of the present invention is characterized in that, when analyzed using differential scanning calorimetry, when the heating rate is 10°C per minute, there is an endothermic peak at 227±5°C and an exothermic peak at 235±5°C in the DSC spectrum ( Figure 4 ). The DSC superposition spectra of bexarotene, metformin and bexarotene-metformin salt are shown in Figure 5 The DSC spectra of bexarotene, metformin and bexarotene-metformin salt showed obvious differences in the number and position of endothermic / exothermic peaks, indicating that bexarotene-metformin salt formed a new solid state.

[0023] 2. Characteristics of the preparation method of bexarotene-metformin salt and mixed solid substance:

[0024] 2.1 The preparation method of bexarotene-metformin salt of the present invention is characterized in that it comprises the following steps:

[0025] (1) dissolving bexarotene and metformin raw materials in a solvent at a molar ratio of 1:0.9 to 1:1.1 to obtain a mixture;

[0026] (2) reacting and crystallizing the mixture obtained in step (1) at 10-50° C. for 2-48 hours;

[0027] (3) separating the solid and liquid phases of the product obtained in step (2) and drying to obtain a solid product of bexarotene-metformin salt.

[0028] 2.2 The solvent in the preparation method of bexarotene-metformin salt involved in the present invention is a mixed solvent prepared by combining any one or more of water, acetone, acetonitrile, ethyl acetate, ethanol, n-propanol, isopropanol, methanol and tetrahydrofuran in different proportions.

[0029] 2.3 The mixed solid material containing bexarotene-metformin salt of the present invention is prepared by mixing the bexarotene-metformin salt component obtained by the above method with other chemical substances in any non-zero ratio and in a conventional manner.

[0030] 3. Compositions of pharmaceutical preparations containing bexarotene-metformin salt, characteristics of dosage and pharmaceutical uses:

[0031] 3.1 The pharmaceutical composition of the present invention comprises bexarotene-metformin salt and a pharmaceutically acceptable carrier.

[0032] 3.2 The pharmaceutical composition of the present invention comprises a mixed solid substance of bexarotene-metformin salt and a pharmaceutically acceptable carrier.

[0033] 3.3 The pharmaceutical composition of the present invention has a daily dosage of bexarotene-metformin salt in the range of 600 to 3000 mg.

[0034] 3.4 The pharmaceutical composition involved in the present invention is characterized in that the pharmaceutical composition is various tablets, capsules, pills, injection preparations, granules, powders, micropills, pellets, suppositories, films, patches, aerosols, sprays, sustained-release preparations or controlled-release preparations.

[0035] 3.5 The present invention relates to the use of bexarotene-metformin salt, mixed solid material or pharmaceutical composition containing bexarotene-metformin salt in the preparation of drugs for preventing and / or treating type 2 diabetes and its related diseases. The type 2 diabetes related diseases include type 2 diabetes psoriasis complications, neuropathy, kidney disease, etc. It improves the psoriasis symptoms of diabetes with psoriasis while lowering blood sugar levels.

[0036] The present invention relates to a pharmaceutical composition with the bexarotene-metformin salt of the present invention as an active ingredient. The pharmaceutical composition can be prepared according to methods known in the art. The bexarotene-metformin salt component of the present invention can be combined with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants to prepare any dosage form suitable for human or animal use. The content of the bexarotene-metformin salt of the present invention in its pharmaceutical composition is in the range of 10% to 90% by weight.

[0037] The bexarotene-metformin salt of the present invention can be administered in a unit dosage form, and the administration route can be enteral or parenteral, mainly oral or transdermal.

[0038] The dosage form of the present invention is preferably a solid dosage form. The solid dosage form can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, pellets, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.

[0039] The bexarotene-metformin salt of the present invention can be prepared into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.

[0040] In order to prepare the bexarotene-metformin salt of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.

[0041] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.

[0042] In order to prepare the dosing unit into a capsule, the active ingredient bexarotene-metformin salt of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient bexarotene-metformin salt of the present invention can also be first made into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. Various diluents, binders, wetting agents, disintegrants, and glidants used to prepare the bexarotene-metformin salt tablets of the present invention can also be used to prepare the capsules of the bexarotene-metformin salt of the present invention.

[0043] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.

[0044] In order to achieve the purpose of medication and enhance the therapeutic effect, the drug of the present invention can be administered by any known administration method.

[0045] The dosage of the bexarotene-metformin salt pharmaceutical composition of the present invention can vary widely depending on the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form, etc. The above dosage can be administered in one dosage unit or divided into several dosage units, depending on the clinical experience of the physician and the dosage regimen including the use of other treatment methods.

[0046] The bexarotene-metformin salt or the composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the bexarotene-metformin salt of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.

[0047] 4 Beneficial technical effects of the present invention: Safety, solubility and biological activity of bexarotene-metformin salt

[0048] Advantageous features.

[0049] 4.1 The bexarotene-metformin salt of the present invention has a DSC spectrum ( Figure 4 ) does not have any endothermic peaks due to loss of crystallization solvent or crystal water, and its thermogravimetric analysis diagram ( Figure 6 ) before decomposition weight loss, indicating that bexarotene-metformin salt does not contain any crystallization solvent and has good safety drug advantages.

[0050] 4.2 The solubility of the bexarotene-metformin salt of the present invention in water system has solubility advantage over bexarotene, which is manifested in that the dissolution rate and apparent solubility are significantly improved ( Figure 7 ).

[0051] 4.3 The drug and drug composition developed with bexarotene-metformin salt as the active ingredient of the present invention have achieved good therapeutic effects on the type 2 diabetes and psoriasis mouse model, and can significantly improve the psoriasis symptoms of type 2 diabetes and psoriasis mice ( Figure 8 , Fig. 9 ), and can significantly improve the abnormal glucose and lipid metabolism in mice with type 2 diabetes and psoriasis ( Fig.10 , Fig.11 The bexarotene-metformin salt of the present invention can simultaneously improve the abnormal glucose and lipid metabolism and psoriasis symptoms of type 2 diabetes with psoriasis, thereby exerting its therapeutic effect.

[0052] Useful technical achievements

[0053] (1) At present, there are no reports on the substance, preparation, characterization and application of bexarotene-metformin salt and mixture.

[0054] (2) Diabetes is one of the most common chronic metabolic diseases worldwide, and diabetic patients are accompanied by a variety of complications. Psoriasis is a common chronic inflammatory disease of the skin. Compared with normal people, psoriasis patients have a higher risk of developing type 2 diabetes, of which about 11.6% of psoriasis patients suffer from type 2 diabetes. Psoriasis is closely related to diabetes, and many patients have both psoriasis and diabetes. At present, there are no reports of oral drugs for the treatment of type 2 diabetes with psoriasis. Bexarotene-metformin salt has the potential to improve blood sugar and psoriasis symptoms at the same time, which will provide a potential therapeutic drug for the treatment of patients with type 2 diabetes and psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 Powder X-ray Diffraction Pattern of Bexarotene-Metformin Salt

[0056] Figure 2 X-ray diffraction pattern of bexarotene-metformin physical mixed powder

[0057] Figure 3 Infrared absorption spectrum of bexarotene-metformin salt

[0058] Figure 4 Differential scanning calorimetry of bexarotene-metformin salt

[0059] Figure 5 Differential scanning calorimetry spectra of metformin, bexarotene and bexarotene-metformin salt

[0060] Figure 6 Thermogravimetric spectrum of bexarotene-metformin salt

[0061] Figure 7 Apparent solubility diagram of bexarotene-metformin salt

[0062] Figure 8 Different doses of bexarotene-metformin salt improve PSAI scores in mice with type 2 diabetes and psoriasis.

[0063] Fig. 9 Improvement of psoriasis skin symptoms in type 2 diabetic psoriasis mice by different doses of bexarotene-metformin salt.

[0064] Fig.10 Effect of different doses of bexarotene-metformin salt on the improvement of fasting blood glucose levels in type 2 diabetic mice with psoriasis.

[0065] Fig.11 Different doses of bexarotene-metformin salt improve plasma glycosylated hemoglobin, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein in mice with type 2 diabetes and psoriasis. DETAILED DESCRIPTION

[0066] The present invention is further described below in conjunction with embodiments, but the present invention is not limited thereto. Without departing from the idea and purpose of the present invention, any changes made to the technical solution of the present invention should fall within the scope defined by the present invention.

[0067] Example 1

[0068] Preparation method 1 of bexarotene-metformin salt:

[0069] Take appropriate amount of bexarotene and metformin in a molar ratio of 1:1 and put them into a clean container, add appropriate amount of methanol, stir for appropriate time for 12 hours at 40°C, filter the obtained suspension solvent and dry it in vacuum, filter it and dry it naturally or evaporate it to dryness. Perform powder X-ray diffraction analysis on it, and its diffraction pattern is similar to Figure 1 The results showed that the obtained sample was bexarotene-metformin salt.

[0070] Preparation method 2 of bexarotene-metformin salt:

[0071] Take metformin hydrochloride and sodium hydroxide or sodium carbonate or other suitable base, put them into a clean container at a molar ratio of 1:1, add an appropriate amount of ethanol, stir for an appropriate time of 8 hours at 30°C, filter, collect all the filtrate, add an equal molar amount of bexarotene, stir for an appropriate time of 8 hours at 30°C, filter the resulting suspension solvent, vacuum dry, filter and dry naturally or evaporate to dryness. Perform powder X-ray diffraction analysis on it, and its diffraction pattern is consistent with Figure 1 The results showed that the obtained sample was bexarotene-metformin salt.

[0072] Preparation method 3 of bexarotene-metformin salt:

[0073] Take metformin hydrochloride and sodium hydroxide or sodium carbonate or other suitable bases in a molar ratio of 1:1, put them in a clean container, add an appropriate amount of organic solvent, stir for an appropriate time (2 to 48 hours) at an appropriate temperature (10-50°C), filter, and evaporate the filtrate at an appropriate temperature to obtain metformin solid powder. Take the above solid powder and an appropriate amount of besaroten in a molar ratio of 1:1, put them in a clean container, add an appropriate amount of organic solvent, stir for an appropriate time (2 to 48 hours) at an appropriate temperature (10-50°C), filter the resulting suspension solvent, vacuum dry it, filter it to dry it naturally, or evaporate it to dry it. Perform powder X-ray diffraction analysis on it, and the diffraction pattern is the same as Figure 1 The results showed that the obtained sample was bexarotene-metformin salt.

[0074] Example 2

[0075] Stability characteristics of bexarotene-metformin salt:

[0076] Light test: 50 mg of bexarotene-metformin salt was placed under light conditions for 5 and 10 days, and powder X-ray diffraction analysis was performed on it. The diffraction pattern was Figure 1 The results showed that the sample was bexarotene-metformin salt, which was stable under light conditions.

[0077] High temperature test: 50 mg of bexarotene-metformin salt was placed under high temperature conditions for 5 days and 10 days, and then subjected to powder X-ray diffraction analysis. The diffraction pattern was similar to Figure 1 The results showed that the sample was bexarotene-metformin salt, which was stable under high temperature conditions.

[0078] High humidity test: 50 mg of bexarotene-metformin salt was placed in high humidity conditions for 5 and 10 days, and then subjected to powder X-ray diffraction analysis. The diffraction pattern was similar to Figure 1 The results showed that the sample was bexarotene-metformin salt and was stable under high humidity conditions.

[0079] Example 3

[0080] In view of the good solubility of metformin itself, this patent compares the in vitro solubility of poorly soluble bexarotene and bexarotene-metformin salt. In pure water, bexarotene-metformin salt exhibits a typical "spring-parachute effect". The dissolution rates of bexarotene-metformin salt in the first 5 minutes were 0.38 μg / mL·min -1The "spring effect" was completed in 15 minutes. At the highest point, the concentration of bexarotene-metformin salt was 9.5 μg / mL, while the bexarotene sample was still not detected at this time. When the 8-h experiment was over, the solubility of bexarotene-metformin salt was still increased by about 3 times compared with bexarotene.

[0081] The concentration of bexarotene in water was used as the evaluation index, and the content was determined by high performance liquid chromatography at a wavelength of 270 nm. The solubility concentration was calculated by external standard method. The apparent solubility curves were drawn with time as the horizontal axis and the solubility concentration as the vertical axis. Figure 7 ). The data is shown in the following table:

[0082] Table 3 Dissolution curve data of bexarotene-metformin salt and bexarotene in water

[0083]

[0084] It can be seen from the experimental data that the dissolution rate and apparent solubility of the bexarotene-metformin salt in water of the present application are significantly better than those of bexarotene.

[0085] The biological materials, drugs and experimental methods used in Experimental Examples 4 to 6 are as follows:

[0086] Drugs: Accurately weigh bexarotene-metformin salt, dissolve it in dimethyl sulfoxide, and then use 0.5% sodium carboxymethylcellulose solution to prepare 10 mg / ml and 5 mg / ml suspensions for animal administration. Accurately weigh streptozotocin, dissolve it in sodium citrate buffer, and prepare a 10 mg / ml streptozotocin solution.

[0087] Establishment of a mouse model of type 2 diabetes with psoriasis and evaluation of the therapeutic effect of bexarotene-metformin salt: 60 male C56 / B6J mice were fed with 60% high-fat diet for 2 weeks. The mice were fasted but not watered, and their weights were weighed and recorded. The tails were cut to collect blood, and the fasting blood glucose values ​​were measured and recorded. The volume of streptozotocin (10 mg / ml) required for each mouse to be injected was calculated according to the dose of 85 mg / kg for two consecutive times (V = 0.085 (mg / g) * body weight (g) / 10 (mg / ml)), and streptozotocin was administered by intraperitoneal injection. Immediately after the injection, the mice were fed with high-fat diet, and the interval between the two injections was two days. After the injection, the fasting blood glucose values ​​of the mice were measured and recorded. The type 2 diabetes model was considered to be successfully established if the fasting blood glucose was > 7.0 mM for two consecutive measurements. The type 2 diabetes model mice were randomly divided into 4 groups, namely A: control group, B: model group, C: low-dose group, and D: high-dose group. After anesthesia with 1.25% Avertin, the hair on the back of the mice was quickly removed, and the back skin was exposed and cleaned, with an area of ​​2cm*3cm. The mice in groups B-D were constructed with a psoriasis lesion model by continuously applying imiquimod cream to the back skin, and the mice in group A were used as a control by applying its cream matrix vaseline. 62.5 mg of 5% concentration imiquimod cream and an equal mass of vaseline cream were weighed out and evenly applied to the back skin of the mice with a rubber stick, and applied continuously for 7 days at a fixed time. During this period, the low-dose group and the high-dose group were given 100 mg / kg and 200 mg / kg of bexarotene-metformin salt by gavage, respectively, and the model group was given an equal amount of 0.5% CMC-Na solution. During the administration period, the observers observed the mice's back skin tissues with naked eyes to see whether there were erythema, desquamation, and obvious thickening of the back skin tissues, and the clinical psoriasis area and severity index (PASI) was used for scoring, including: erythema, desquamation, and skin thickening. On the first day after the end of the administration, the fasting blood glucose level of the mice was detected and recorded.

[0088] Detection of sugar and lipid metabolism related indicators: Eyeballs of mice were removed to collect blood, which was collected in a 1.5 mL EP tube containing sodium heparin and centrifuged at 5000 rpm and 4°C for 15 min. The supernatant obtained by centrifugation was plasma. The plasma was aliquoted and stored at -80°C for later use. The corresponding sugar and lipid metabolism indicators were detected using the glycosylated serum protein detection kit, triglyceride detection kit, total cholesterol detection kit, low-density lipoprotein cholesterol detection kit, and high-density lipoprotein cholesterol detection kit.

[0089] Example 5

[0090] (1) Low-dose (100 mg / kg) and high-dose (200 mg / kg) bexarotene and metformin salt were administered to mice for seven consecutive days. PASI scores were performed on the back skin of mice every day. The scores of erythema, desquamation, and skin thickening were recorded (0-4 points) and the total score was calculated. The results are shown in Table 1. Figure 8 Compared with the model group, 100mg / kg and 200mg / kg of bexarotene-metformin salt can significantly improve the scores of erythema, desquamation and skin thickening as well as the total PASI score.

[0091] (2) On the last day of drug administration, take photos to record the skin condition on the back of the mice. Fig. 9 Compared with the model group, the low-dose group (100 mg / kg) and high-dose group (200 mg / kg) of bexarotene-metformin salt can significantly improve the psoriasis skin lesions in mice.

[0092] Example 6

[0093] After the administration, the mice were fasted but not watered, and their fasting blood glucose levels were tested. The relative blood glucose change was calculated based on the fasting blood glucose values ​​before and after administration. The results are shown in Table 1. Fig.10 Compared with the model group, low dose (100 mg / kg) and high dose (200 mg / kg) of bexarotene-metformin salt can reduce the fasting blood glucose level of mice, among which 200 mg / kg of bexarotene and metformin salt can significantly reduce the fasting blood glucose level of mice.

[0094] After the administration, the eyeballs of mice were removed to collect blood, which was collected in 1.5 mL EP tubes containing sodium heparin and centrifuged at 5000 rpm for 15 min at 4 °C. After the supernatant plasma was obtained by centrifugation, plasma glycosylated serum protein, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were tested. The results are as follows: Fig.11 As shown. It can be seen that compared with the model group, 100 mg / kg and 200 mg / kg of bexarotene-metformin salt can reduce the levels of plasma glycosylated serum protein, triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mice and increase the level of high-density lipoprotein cholesterol.

Claims

1. A bexarotene-metformin salt as shown in formula I, characterized in that: Bexarotene and metformin form a salt in a molar ratio of 1:1; 2. The bexarotene-metformin salt according to claim 1, characterized in that When using powder X-ray diffraction analysis using CuK α Under radiation experimental conditions, diffraction peak position: 2-Theta value (°) or d value Diffraction peak relative intensity: peak height value (Height%) or peak area value (Area%) has the following characteristics:

3. The bexarotene-metformin salt according to claim 1, characterized in that When analyzed by attenuated total reflection Fourier transform infrared spectroscopy, 3671, 3497, 3397, 3269, 3018, 2949, 2927, 2862, 1812, 1715, 1669, 1616, 1584, 1538, 1531, 1505, 1462, 1454, 1411, 1378, 1319, 1280, 1268, 1 227, 1186, 1168, 1142, 1111, 1104, 1077, 1064, 1049, 1018, 963, 924, 906, 898, 868, 850, 843, 795, 764, 725, 649, 629, 589, 567, 549, 534, 518, 489, 472, 460, 423, 414cm -1 There is a characteristic peak of infrared spectrum at the position, and the allowable deviation of the characteristic peak of infrared spectrum is ±2cm -1 .

4. The bexarotene-metformin salt according to claim 1, when analyzed using differential scanning calorimetry technology, shows that when the heating rate is 10°C per minute, there is an endothermic peak at 227±5°C and an exothermic peak at 235±5°C in the DSC spectrum.

5. The method for preparing the bexarotene-metformin salt according to any one of claims 1 to 4, characterized in that: The following steps are involved: (1) dissolving bexarotene and metformin raw materials in a solvent at a molar ratio of 1:0.9 to 1:1.1 to obtain a mixture; (2) reacting and crystallizing the mixture obtained in step (1) at 10-50° C. for 2-48 hours; (3) separating the solid and liquid phases of the product obtained in step (2) and drying to obtain a solid product of bexarotene-metformin salt.

6. The preparation method according to claim 5, characterized in that The solvent is a mixed solvent prepared by combining any one or more of water, acetone, acetonitrile, ethyl acetate, ethanol, n-propanol, isopropanol, methanol and tetrahydrofuran in different proportions.

7. A mixed solid material containing bexarotene-metformin salt, characterized in that: The amount of the bexarotene-metformin salt according to any one of claims 1 to 4 is 1-99.9%, preferably 10-99.9%, more preferably 50-99.9%, and most preferably 85-99.9%.

8. A pharmaceutical composition, characterized in that Contains an effective dose of the bexarotene-metformin salt according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition, characterized in that Containing an effective dose of the bexarotene-metformin salt according to claim 7 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to any one of claims 8 or 9, characterized in that The daily dosage of bexarotene-metformin salt is in the range of 600-3000 mg.

11. A pharmaceutical composition according to any one of claims 8 or 9, characterized in that The dosage form of the pharmaceutical composition is tablets, capsules, pills, injection preparations, granules, powders, pellets, dropping pills, suppositories, films, patches, aerosols, sprays, sustained-release preparations or controlled-release preparations.

12. Use of the bexarotene-metformin salt according to any one of claims 1 to 4, the mixed solid material containing bexarotene-metformin salt according to claim 7, or the pharmaceutical composition according to any one of claims 8 to 11 in the preparation of a drug for preventing and / or treating type 2 diabetes and related diseases.

13. Use according to claim 12, characterized in that The type 2 diabetes related diseases include type 2 diabetes psoriasis complications, neuropathy, kidney disease and the like.